Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator
Novel Approach Has Potential for Treatment of Multiple CNS Disorders
25-Jun-2009 -
Addex Pharmaceuticals announced that its partner Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression ...
anxiety
clinical trials
CNS disorders
+3